Clinical significance of expression of vascular endothelial growth factor in epithelial ovarian cancer

doi:10.3877/cma.j.issn.1673-5250.2017.01.006

Objective

To analyze the clinical significance of expression of vascular endothelial growth factor (VEGF) in epithelial ovarian cancer (EOC).

Methods

A total of 65 cases of EOC patients who underwent surgery for the first time and postoperative chemotherapy in West China Second University Hospital from October 2003 to July 2008, and had complete clinical and pathological data were included as research subjects. VEGF expressions of archived specimens of the 65 patients were detected by immunohistochemical method. According to the expression of VEGF were positive or negative, those 65 patients were divided into VEGF⁺ group and VEGF^- group, respectively. The age, International Federation of Gynecology and Obstetrics (FIGO) stage, degree of differentiation, with or without lymph node metastasis and (or) vascular invasion, pathological type, platinum-resistant or platinum-sensitive between two groups were analyzed by statistical methods.

Results

① Among those 65 cases patients with EOC, 35 cases were VEGF⁺ and they were included into VEGF⁺ group. 30 cases were VEGF^- and they were included into VEGF^- group. ②There were no statistical differences between two groups in age, constituent ratios of with or without lymph node metastasis and (or) vascular invasion, pathological type, platinum-resistant or platinum-sensitive (P>0.05). The proportion of advanced FIGO stage (Ⅲ-Ⅳ stage) patients of VEGF⁺ group was higher than that of VEGF^- group, and the difference was statistically significant (χ²=6.49, P=0.02). The proportion of patients with middle to low differentiation of VEGF⁺ group was higher than that of VEGF^- group, and the difference was statistically significant (χ²=4.97, P=0.04).

Conclusions

Postoperative chemotherapy combined with VEGF inhibitor may improve curative effect in patients with EOC in FIGO Ⅲ-Ⅳ stage, middle to low differentiation. We can not predict platinum-based chemotherapy drugs resistance by detecting VEGF expression.

Key words: Vascular endothelial growth factor, Epithelial ovarian cancer, Platinum-based chemotherapy drugs, Drugs resistance, neoplasm

表1 2组上皮性卵巢癌患者一般临床资料比较

组别	例数	年龄(岁,±s)	FIGO临床分期[例数(%)]		肿瘤组织分化程度		淋巴结转移和(或)脉管浸润
组别	例数	年龄(岁,±s)	Ⅰ～Ⅱ期	Ⅲ～Ⅳ期	高分化	中、低分化	有	无
VEGF^＋组	35	51.1±9.7	7(20.0)	28(80.0)	0(0)	4(13.3)	15(42.9)	12(40.0)
VEGF^－组	30	48.7±7.6	15(50.0)	15(50.0)	35(10.0)	26(86.7)	20(57.1)	18(60.0)
检验值	?	t＝1.11	χ²＝6.49		χ²＝4.97		χ²＝0.05
P值	?	0.27	0.02		0.04		0.82
组别	例数	肿瘤组织病理类型					铂类药物耐药或敏感
组别	例数	宫内膜样腺癌	浆液性腺癌	透明细胞癌	腺鳞癌	混合性腺癌	耐药	敏感
VEGF^＋组	35	3(8.6)	24(68.6)	3(8.6)	1(2.8)	4(11.4)	14(40.0)	21(60.0)
VEGF^－组	30	6(20.0)	18(60.0)	5(16.7)	1(3.3)	0(0)	10(33.3)	20(66.7)
检验值	?	χ²＝6.01					χ²＝0.31
P值	?	0.20					0.62

表1 2组上皮性卵巢癌患者一般临床资料比较

组别	例数	年龄(岁,±s)	FIGO临床分期[例数(%)]		肿瘤组织分化程度		淋巴结转移和(或)脉管浸润
组别	例数	年龄(岁,±s)	Ⅰ～Ⅱ期	Ⅲ～Ⅳ期	高分化	中、低分化	有	无
VEGF^＋组	35	51.1±9.7	7(20.0)	28(80.0)	0(0)	4(13.3)	15(42.9)	12(40.0)
VEGF^－组	30	48.7±7.6	15(50.0)	15(50.0)	35(10.0)	26(86.7)	20(57.1)	18(60.0)
检验值	?	t＝1.11	χ²＝6.49		χ²＝4.97		χ²＝0.05
P值	?	0.27	0.02		0.04		0.82
组别	例数	肿瘤组织病理类型					铂类药物耐药或敏感
组别	例数	宫内膜样腺癌	浆液性腺癌	透明细胞癌	腺鳞癌	混合性腺癌	耐药	敏感
VEGF^＋组	35	3(8.6)	24(68.6)	3(8.6)	1(2.8)	4(11.4)	14(40.0)	21(60.0)
VEGF^－组	30	6(20.0)	18(60.0)	5(16.7)	1(3.3)	0(0)	10(33.3)	20(66.7)
检验值	?	χ²＝6.01					χ²＝0.31
P值	?	0.20					0.62

[1]	Siegel R, Ward E, Brawley O, et al. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths[J]. CA Cancer J Clin, 2011, 61(4): 212-236.
[2]	Cao Y. Angiogenesis: what can it offer for future medicine[J]. Exp Cell Res, 2010, 316(8): 1304-1308.
[3]	Ueda M, Terai Y, Kumagai K, et al. Vascular endothelial growth factor C gene expression is closely related to invasion phenotype in gynecological tumor cells[J]. Gynecol Oncol, 2001, 82(1): 162-166.
[4]	谢幸,苟文丽,主编. 妇产科学. 8版[M]. 北京：人民卫生出版社,2013: 322.
[5]	Tavassoli FA, Devilee P. 乳腺及女性生殖器官肿瘤病理学和遗传学[M]. 程虹,蛾林,郭双平,等,译. 北京：人民卫生出版社,2006: 142-179.
[6]	Morgan RJJr, Armstrong DK, Alvarez RD, et al. Ovarian cancer, version 1. 2016, NCCN Clinical Practice Guidelines in Oncology[J]. J Natl Compr Canc Netw, 2016, 14(9): 1134-1163.
[7]	Ngan HY, Odicino F, Maisonneuve P, et al. Gestational trophoblastic neoplasia. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer[J]. Int J Gynaecol Obstet, 2006, 95(Suppl 1): S193-S203.
[8]	Davis A, Tinker AV, Friedlander M. " Platinum resistant" ovarian cancer: what is it, who to treat and how to measure benefit？[J]. Gynecol Oncol, 2014, 133(3): 624-631.
[9]	Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer[J]. N Engl J Med, 2011, 365(26): 2473-2483.
[10]	Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer[J]. N Engl J Med, 2011, 365(26): 2484-2496.
[11]	Oza AM, Perren TJ, Swart AM, et al. ICON 7: final overall survival results in the GCIG phase Ⅲ randomised trial of bevacizumab in women with newly diagnosed ovarian cancer[J]. E J Cancer, 2013, 49(Suppl 3): S4.
[12]	Aghajanian C, Blank SV, Goff BA, et al. OCEANS: a randomized, double-blind, placebo-controlled phase Ⅲ trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer[J]. J Clin Oncol, 2012, 30(17): 2039-2045.
[13]	Pujade-Lauraine E, Hilpert F, Weber B, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase Ⅲ trial[J]. J Clin Oncol, 2014, 32(13): 1302-1308.
[14]	杨丽娜,吴娟,赵静,等. Twist和VEGF在上皮性卵巢癌中的表达[J]. 西安交通大学学报(医学版), 2015, 36(3): 341-344.
[15]	朱勇杰,师晓莉,沈妮娜,等. 血管内皮生长因VEGF-C和VEGF-D在卵巢上皮癌的表达及其预后研究[J]. 新疆大学学报,2014, 37(12): 1591-1594.
[16]	徐小博,张西愿,王建,等. MMP-2和VEGF在上皮性卵巢肿瘤中的表达及临床意义[J]. 中国妇幼健康研究,2014, 25(5): 764-767.
[17]	Randall L, Burger R, Nguyen H, et al. Outcome differences in patients with advanced epithelial ovarian, primary peritoneal and fallopian tube cancers treated with and without bevacizumab[J]. Gynecol Oncol, 2013, 130(1): e33-e34.

[1]	Xiaoli Shao, Yan Lin, Lingling Zhang, Yaqin Han. Clinical efficacy of uterus myoma injection of lauromacrogol sclerotherapy by ultrasound-guided combined with postoperative mifepristone[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2024, 20(03): 353-360.
[2]	Huizhu Chen, Yingkun Guo, Xinrong Wang, Gang Ning, Xijian Chen. Current research status on the " dualistic model" of epithelial ovarian cancer and its molecular biology[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2023, 19(04): 394-402.
[3]	Wei Liu, Jie An, Lianghui Zhi, Jinhui Chen. Apatinib combined with neoadjuvant chemotherapy in locally advanced colon cancer: A clinical efficacy study[J]. Chinese Archives of General Surgery(Electronic Edition), 2024, 18(03): 199-203.
[4]	Bo Wang, Zirui Bai, Jian Li. Preparation of a novel VEGFR-targeting probe second near-infrared window in a mouse model of colorectal cancer[J]. Chinese Archives of General Surgery(Electronic Edition), 2023, 17(03): 173-177.
[5]	Fu Huang, Qian Wang, Xiangren Jin, Yunchuan Tang. Study on the relationship between the expression of VEGFR2 and miR-27a-5p in gastric cancer tissues and clinicopathological parameters and prognosis[J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(05): 558-561.
[6]	Jialin Zhu, Xiang Fang, Shiyu Gui, Dan Huang, Xiaoyu Zhou, Wenkai Guo. Expression of VEGF and Ang-1 in serum after incisional hernia preperitoneal gap patch repair in rats[J]. Chinese Journal of Hernia and Abdominal Wall Surgery(Electronic Edition), 2024, 18(06): 703-707.
[7]	Hui Yang, Lijuan Guo, Xiaodan Feng, Jing LI, Chengmo Huang, Xingrui Cai, Yingjiao Qin, Yuanli Wang. Expression characteristics and prediction analysis of platinum-resistant mi RNA in non-small cell lung cancer[J]. Chinese Journal of Lung Diseases(Electronic Edition), 2024, 17(05): 719-724.
[8]	Minlong Zhang, Cuiping Yang, Bo Wang, Yunjie Cui, Faguang Jin. miR-200b-3p suppressed the edema in seawater aspiration-induced ALI via inhibition the expression of HIF-1α[J]. Chinese Journal of Lung Diseases(Electronic Edition), 2024, 17(05): 696-700.
[9]	Jing Bao, Xia Wu, Yaping Tian, Gang Yin. Effects of vitamin D₃ combined with Montelukast sodium on serum VEGF, TGF-β1 and lung function in patients with bronchial asthma[J]. Chinese Journal of Lung Diseases(Electronic Edition), 2024, 17(01): 63-67.
[10]	Ying Zhu, Zheng Zhao, Da Xu, Lu Lu, Baobing Yin. Progress and prospect of immune checkpoint inhibitors in the treatment of hepatocellular carcinoma[J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(01): 5-10.
[11]	Han Liu, Qiang Shen, Lanyue Zhang, Jian Chen. Research progress on molecular biomarkers of diabetic retinopathy[J]. Chinese Journal of Ophthalmologic Medicine(Electronic Edition), 2023, 13(06): 376-380.
[12]	Hongyu Cui, Yiquan Yang, Lixia Guo, Aiguo Lyn, Zhihong Zhang, Xin Zhang, Yanping Yang, Ran Shen, Liying Lian, Zhigang Cao, Lifang Wang, Jianhua Hu, Sujie Fan. The effect of modified Ahmed glaucoma valve implantation on neovascular glaucoma at the angle-closure stage[J]. Chinese Journal of Ophthalmologic Medicine(Electronic Edition), 2023, 13(02): 76-81.
[13]	Jianbo Song, Junwei Han, Min Zhou, Hongping Wen. Risk of proteinuria associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a Meta-analysis[J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(12): 1297-1303.
[14]	Qing Huang, Ruiheng Zhao, Huiying Qian. PCI-24781, a histone deacetylase inhibitor, induces apoptosis of SKOV-3 cells via multiple mechanisms[J]. Chinese Journal of Clinicians(Electronic Edition), 2022, 16(08): 775-781.
[15]	Fanhui Yan, Mingli Zhao, Ying Li, Fangming Guo, Jingdong Zhan, Yingjie Zhao, Yang Wang, Yanfen Zhang, Xiaomei Zhao. Study on the correlation between the degree of coronary vascular lesion and serum levels of TNF-α and VEGF in patients with acute coronary syndrome[J]. Chinese Journal of Diagnostics(Electronic Edition), 2023, 11(03): 158-164.

Viewed

Full text

Abstract

Please choose a citation manager

Content to export